UCT BIOSCIENCE

The disruptive innovation carried out in this project is assembling a technology platform by conjugating our newly developed Fn-Cancer Targeting Peptide (FnCTP) acting as a warhead, with a variety of payloads (including bispecific antibodies, monoclonal antibodies, small molecule drugs, antisense oligo / siRNA, and CAR- T). Characteristics are described as follows: 1.New scientific breakthrough that leads to 'one-size-fitsall' cancer treatment; 2.Low toxicity against normal cells / tissues; 3.Se... lectively kill the cancer stem cells. The team recruited cross-domain experts including Dr. Alice L. Yu, Prof. John Yu, and Dr. Chia-Cheng Wu to jointly develop two products: 1. FnCTP-conjugated anti-CD3 BsAb (FnCTP-BsAb) that serves as targeted therapy for a broad spectrum of cancers, or so-called one model fit-for-all cancers; 2. FnCTP-conjugated nanocomplex containing Herceptin (FnCTP-MNC-Herceptin) that is used to represent the prototype of novel cancer treatment. After completing Proof of Concept and pre-clinical studies, we will file a patent application for these products and then proceed to technical transfer. Founded in Sep 2019, UCT Bioscience Inc., a biotech startup, has recruited Dr. Chia-Cheng Wu as CEO. Apart from moving on with the clinical development of FnCTP-BsAb, UCT Bioscience is utilizing its FnCTP platform to develop a broad range of anti-cancer drugs, through collaboration with international pharmaceutical companies.More